Aim Immunotech Stock Price, News & Analysis

AIM ImmunoTech (NYSE American: AIM) announced that data from a completed Phase 2 cisplatin-resistant advanced recurrent ovarian cancer study using Ampligen (rintatolimod) was accepted as a late‑breaking abstract for presentation at the 40th Annual SITC Meeting (November 5-9, 2025) in National Harbor, MD.

Poster details: Title: A Phase II Trial of Combination Locoregional Chemoimmunotherapy in Recurrent Platinum-Sensitive Ovarian Cancer Triggers a T Lymphotactic Response Correlating with Clinical Outcomes; Presenting author: Mackenzy M. Radolec, MD; Abstract #1343; Date: Friday, November 7, 2025; Location: Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center.

AIM (NYSE American: AIM) announced on Nov 3, 2025 that the European Patent Office granted European Patent No. 4,096,675 for "Compositions for Treating LONG COVID," covering compositions of AIM’s dsRNAs including Ampligen (rintatolimod) for use in treating Long COVID.

The release notes prior in vitro, preclinical and clinical evidence, cites decreased SARS‑CoV‑1 replication and >90% structural homology with SARS‑CoV‑2, and references positive topline results from the Phase 2 AMP‑518 study reporting Ampligen was generally well tolerated with efficacy signals for reducing post‑COVID fatigue.

AIM ImmunoTech (NYSE American: AIM) will participate at the 2025 Maxim Growth Summit in New York on October 22–23, 2025.

Company management will be available for in-person one-on-one meetings with qualified, registered investors, and the presentation slide deck is available on the company's Presentations page at aimimmuno.com. For the full summit agenda, visit the Maxim Growth Summit website.

AIM ImmunoTech (NYSE American: AIM) has secured a significant patent in Japan for its cancer therapy combining Ampligen® (Rintatolimod) with checkpoint inhibitors, valid through 2039. The patent covers multiple cancer types and strengthens AIM's position in the world's third-largest pharmaceutical market.

The broad patent claims encompass treatments for pancreatic, skin, colorectal, ovarian, melanoma, breast, head and neck, bladder, renal cell, and lung cancers. AIM holds similar patents in the U.S. (expires 2039) and Netherlands (expires 2039) for Ampligen combination therapies.

The company is currently conducting a Phase 2 trial with AstraZeneca, combining Ampligen with durvalumab for metastatic pancreatic cancer, showing promising survival results. Additionally, a Phase 2 study with Merck combining Ampligen with Keytruda for advanced recurrent ovarian cancer awaits final data reports.

AIM ImmunoTech (NYSE American: AIM) announced the publication of a significant peer-reviewed article in the Journal for ImmunoTherapy of Cancer. The research demonstrates a positive combination effect of AIM's drug Ampligen when used with interferon-alpha on tumor growth and patient survival.

The study reveals that systemic chemokine modulation can overcome PD-1 resistance in cold tumors, highlighting that intratumoral cytotoxic t-lymphocyte accumulation is the crucial factor in immune checkpoint inhibitor effectiveness. The findings suggest promising potential for tumor microenvironment reprogramming strategies in cancer treatment.

AIM ImmunoTech (NYSE American: AIM) presented the latest progress of its lead drug candidate Ampligen for pancreatic cancer treatment at the 5th Annual Marie Skłodowska-Curie Symposium in Poland. The presentation highlighted positive data from both the Phase 2 DURIPANC clinical trial and an Early Access Program, focusing on Progression-Free Survival and Overall Survival metrics.

The company's ongoing Phase 2 DURIPANC study evaluates Ampligen in combination with AstraZeneca's durvalumab for treating late-stage metastatic pancreatic cancer. Notably, Ampligen has secured patent protection through 2039 and holds both US and EU orphan drug designations for market protection upon approval.

AIM ImmunoTech (NYSE American: AIM) has released its latest CEO Corner segment featuring CEO Thomas Equels. The segment, now available on the company's website, provides a comprehensive corporate update and focuses on the development progress of Ampligen, the company's lead product candidate, particularly in pancreatic cancer treatment.

The update includes details about recent scientific advancements and the company's strategic direction in advancing Ampligen's development program.

AIM ImmunoTech (NYSE:AIM) has reported its Q2 2025 financial results and provided updates on its pipeline programs. The company's primary focus remains on its Phase 2 DURIPANC trial evaluating Ampligen in combination with AstraZeneca's Imfinzi for pancreatic cancer treatment, which has shown promising signs regarding toxicity, progression-free survival (PFS), and overall survival (OS).

The company recently raised $8.0 million through a public offering in July 2025, extending its operational runway for approximately 12 months. Financial results show a net loss of $2.8 million ($3.68 per share) for Q2 2025, compared to $1.8 million ($3.00 per share) in Q2 2024. Cash position stood at $835,000 as of June 30, 2025.

AIM ImmunoTech (NYSE American: AIM) announced its participation in the upcoming Webull Financial Corporate Connect Webinar Series focused on Biotech/MedTech companies. The virtual presentation will be delivered by Thomas Equels, the company's CEO, President & Executive Vice Chairman, on Wednesday, August 20, 2025 at 2:40 PM ET. The event is part of a larger virtual conference taking place from August 19-21, 2025.